Anti-PAR6G/ PARD6G/ PAR-6G monoclonal antibody

Anti-PAR6G/ PARD6G/ PAR-6G antibody for FACS & in-vivo assay

Target products collectionGo to PARD6G/PARD6G products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP2235-Ab-1/ GM-Tg-hg-MP2235-Ab-2Anti-Human PARD6G monoclonal antibodyHuman
GM-Tg-rg-MP2235-Ab-1/ GM-Tg-rg-MP2235-Ab-2Anti-Rat PARD6G monoclonal antibodyRat
GM-Tg-mg-MP2235-Ab-1/ GM-Tg-mg-MP2235-Ab-2Anti-Mouse PARD6G monoclonal antibodyMouse
GM-Tg-cynog-MP2235-Ab-1/ GM-Tg-cynog-MP2235-Ab-2Anti-Cynomolgus/ Rhesus macaque PARD6G monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP2235-Ab-1/ GM-Tg-felg-MP2235-Ab-2Anti-Feline PARD6G monoclonal antibodyFeline
GM-Tg-cang-MP2235-Ab-1/ GM-Tg-cang-MP2235-Ab-2Anti-Canine PARD6G monoclonal antibodyCanine
GM-Tg-bovg-MP2235-Ab-1/ GM-Tg-bovg-MP2235-Ab-2Anti-Bovine PARD6G monoclonal antibodyBovine
GM-Tg-equg-MP2235-Ab-1/ GM-Tg-equg-MP2235-Ab-2Anti-Equine PARD6G monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP2235-Ab-1/ GM-Tg-hg-MP2235-Ab-2; GM-Tg-rg-MP2235-Ab-1/ GM-Tg-rg-MP2235-Ab-2;
GM-Tg-mg-MP2235-Ab-1/ GM-Tg-mg-MP2235-Ab-2; GM-Tg-cynog-MP2235-Ab-1/ GM-Tg-cynog-MP2235-Ab-2;
GM-Tg-felg-MP2235-Ab-1/ GM-Tg-felg-MP2235-Ab-2; GM-Tg-cang-MP2235-Ab-1/ GM-Tg-cang-MP2235-Ab-2;
GM-Tg-bovg-MP2235-Ab-1/ GM-Tg-bovg-MP2235-Ab-2; GM-Tg-equg-MP2235-Ab-1/ GM-Tg-equg-MP2235-Ab-2
Products NameAnti-PARD6G monoclonal antibody
Formatmab
Target NamePARD6G
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-PARD6G benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species PAR6G/ PARD6G/ PAR-6G VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP2235
    Target NamePARD6G
    Gene ID84552,93737,307237,699479,483923,105261071,539292,100065587
    Gene Symbol and Synonyms2410049N21Rik,PAR-6G,Par6a,PAR6gamma,PARD6G
    Uniprot AccessionQ9BYG4
    Uniprot Entry NamePAR6G_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000178184
    Target ClassificationN/A

    The target: PARD6G, gene name: PARD6G, also named as PAR-6G, PAR6gamma. Predicted to enable protein kinase C binding activity. Predicted to be involved in centrosome cycle; establishment or maintenance of cell polarity; and regulation of cellular localization. Predicted to be located in cytosol and plasma membrane. Predicted to be part of protein-containing complex. Predicted to be active in apical plasma membrane; cell cortex; and nucleus. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.